This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Valero, V. Articles by Hortobagyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Valero, V. Articles by Hortobagyi, G. N. Social Bookmarking                            What's this?

Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer

From the University of Texas M.D. Anderson Cancer Center, Houston, TX; and The Liposome Company, Inc, Princeton, NJ.

Address reprint requests to Vicente Valero, MD, University of Texas M.D. Anderson Cancer Center, Department of Breast Medical Oncology, 1515 Holcombe Blvd, Box 56, Houston, TX 77030; email vvalero{at}mdacc.org

PURPOSE: To determine the efficacy and safety profile, including the risk for cardiac toxicity, of liposome-encapsulated doxorubicin (TLC D-99), fluorouracil (5-FU), and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer (MBC).

PATIENTS AND METHODS: Forty-one women were registered in this phase II study. All patients had measurable disease and no previous chemotherapy for MBC. Treatment consisted of TLC D-99 60 mg/m² and cyclophosphamide 500 mg/m² on day 1 and 5-FU 500 mg/m² on days 1 and 8 every 3 weeks. Serial cardiac monitoring, including endomyocardial biopsies, was performed.

RESULTS: The overall response rate was 73% (95% confidence interval, 57% to 86%). The median duration of response was 11.2 months, the median time to treatment failure was 8.1 months, and the median overall survival duration was 19.4 months. The median number of cycles per patient was 10. The median cumulative dose of TLC D-99 was 528 mg/m². Ten patients required hospitalization for febrile neutropenia. Nausea/vomiting, stomatitis, and fatigue higher than grade 2 occurred in 12%, 15%, and 41% of patients, respectively. Twenty-one patients reached a cumulative doxorubicin dose greater than 500 mg/m². Three patients (7%) were withdrawn from the study due to protocol-defined cardiac toxicity, two because of a decrease in left ventricular ejection fraction to 40%, and one because her endomyocardial biopsy result was grade 1.5. One patient had congestive heart failure that was probably nonanthracycline related.

CONCLUSION: This chemotherapy regimen, including TLC D-99, was highly active against MBC and associated with low cardiac toxicity despite high cumulative doses of doxorubicin.

Presented in part at the Chemotherapy Foundation Symposium XII, November 9-11, 1994, New York, NY, and at the 14th Annual Meeting of the American Society of Clinical Oncology, May 15-18, 1995, Los Angeles, CA.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology Eur. Heart J., December 2, 2007; 28(24): 3076 - 3093. [Full Text] [PDF]

				L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1914 - 1931. [Full Text] [PDF]

				L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Circulation, November 6, 2007; 116(19): 2216 - 2233. [Full Text] [PDF]

				E. Mrozek, C. A. Rhoades, J. Allen, E. M. Hade, and C. L. Shapiro Phase I trial of liposomal encapsulated doxorubicin (MyocetTM; D-99) and weekly docetaxel in advanced breast cancer patients Ann. Onc., July 1, 2005; 16(7): 1087 - 1093. [Abstract] [Full Text] [PDF]

				S. Chan, N. Davidson, E. Juozaityte, F. Erdkamp, A. Pluzanska, N. Azarnia, and L. W. Lee Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Ann. Onc., October 1, 2004; 15(10): 1527 - 1534. [Abstract] [Full Text] [PDF]

				S. A. Abraham, C. McKenzie, D. Masin, R. Ng, T. O. Harasym, L. D. Mayer, and M. B. Bally In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading Clin. Cancer Res., January 15, 2004; 10(2): 728 - 738. [Abstract] [Full Text] [PDF]

				E. Rivera Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update Oncologist, August 1, 2003; 8(90002): 3 - 9. [Abstract] [Full Text] [PDF]

				S. Campos Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer Oncologist, August 1, 2003; 8(90002): 10 - 16. [Abstract] [Full Text] [PDF]

				G. N Hortobagyi Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 72 - 79. [Abstract] [Full Text] [PDF]

				F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond Oncologist, April 1, 2001; 6(2): 133 - 146. [Abstract] [Full Text]

				G. Batist, G. Ramakrishnan, C. S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, P. Shah, A. Khojasteh, M. K. Nair, K. Hoelzer, et al. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer J. Clin. Oncol., March 1, 2001; 19(5): 1444 - 1454. [Abstract] [Full Text] [PDF]

				D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors Pharmacol. Rev., December 1, 1999; 51(4): 691 - 744. [Abstract] [Full Text] [PDF]